Hereditary colorectal cancer syndromes: An overview

Clinical Colorectal Cancer

Volumn 6, Issue 5, 2007, Pages 340-344

  Kwak, Eunice L ^a   Chung, Daniel C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Adenomatous polyposis; Genetics; High penetrance syndrome

Indexed keywords

FLUOROURACIL;

ADENOMATOUS POLYP; ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RISK; CANCER STAGING; COLORECTAL CANCER; FAMILIAL CANCER; FAMILY HISTORY; GENE MUTATION; GENETIC ANALYSIS; GENETIC COUNSELING; HUMAN; METHYLATION; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; REVIEW;

EID: 33847382860     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2007.n.002     Document Type: Review

References (38)

1. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352:476-487.
2. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003; 348:919-932.
3. Smith RA, von Eschenbach AC, Wender R, et al. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. CA Cancer J Clin 2001; 51:38-75.
4. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005; 352:1851-1860.
5. Jo WS, Chung DC. Genetics of hereditary colorectal cancer. Semin Oncol 2005; 32:11-23.
6. Chung DC. The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterology 2000; 119:854-865.
7. Guillem JG, Wood WC, Moley JF, et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 2006; 24:4642-4660.
8. Giardiello FM, Yang VW, Hylind LM, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002; 346:1054-1059.
9. Bjork J, Akerbrant H, Iselius L, et al. Periampullary adenomas and adenocarcinomas in familial adenomatous polyposis: cumulative risks and APC gene mutations. Gastroenterology 2001; 121:1127-1135.
10. Chung DC, Mino M, Shannon KM. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 34-2003. A 45-year-old woman with a family history of colonic polyps and cancer. N Engl J Med 2003; 349:1750-1760.
11. Burt RW, Leppert MF, Slattery ML, et al. Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis. Gastroenterology 2004; 127:444-451.
12. Slupska MM, Baikalov C, Luther M, et al. Cloning and sequencing a human homolog (hMYH) of the Escherichia coli mutY gene whose function is required for the repair of oxidative DNA damage. J Bacteriol 1996; 178:3885-3892.
13. Lipton L, Tomlinson I. The multiple colorectal adenoma phenotype and MYH, a base excision repair gene. Clin Gastro Hepat 2004; 2:633-638.
14. Al-Tassan N, Chmiel NH, Maynard J, et al. Inherited variants of MYH associated with somatic G:C→T:A mutations in colorectal tumors. Nat Genet 2002; 30:227-232.
15. Sieber OM, Lipton L, Crabtree M, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 2003; 348:791-799.
16. Farrington SM, Tenesa A, Barnetson R, et al. Germline susceptibility to colorectal cancer due to base-excision repair defects. Am J Hum Genet 2005; 77:112-119.
17. Peterlongo P, Mitra N, Chuai S, et al. Colorectal cancer risk in individuals with biallelic or monoallelic mutations of MYH. Int J Cancer 2005; 114:505-507.
18. Jenkins MA, Croitoru ME, Monga N, et al. Risk of colorectal cancer in monoallelic and biallelic carrier of MYH mutations: a population-based case-family study. Cancer Epidem Biomar 2006; 15:312-314.
19. Chung DC, Rustgi AK. The hereditary nonpolyposis colorectal cancer syndrome: genetic and clinical implications. Ann Intern Med 2003; 138:560-570.
20. Hendriks YM, de Jong AE, Morreau H, et al. Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA Cancer J Clin 2006; 56:213-225.
21. Vasen H, Wijnen J, Menko F, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996; 110:1020-1028.
22. Watson P, Lynch H. Cancer risk in mismatch repair gene mutation carriers. Familial Cancer 2001; 1:57-60.
23. Hampel H, Stephens JA, Pukkala E, et al. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 2005; 129:415-421.
24. Hampel H, Frankel W, Panescu J, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 2006; 66:7810-7817.
25. Lipton LR, Johnson V, Cummings C, et al. Refining the Amsterdam Criteria and Bethesda Guidelines: testing algorithms for the prediction of mismatch repair mutation status in the familial cancer clinic. J Clin Oncol 2004; 22:4934-4943.
26. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96:261-268.
27. Peltomaki P. Lynch syndrome genes. Fam Cancer 2005; 4:227-232.
28. Pinol V, Castells A, Andreu M, et al. Accuracy of revised Bethesda Guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 2005; 293:1986-1994.
29. Lindor NM, Burgart LJ, Leontovich O, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002; 20:1043-1048.
30. Wahlberg SS, Schmeits J, Thomas G, et al. Evaluation of microsatellite instability and immunohistochemistry for the prediction of germline MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. Cancer Res 2002; 62:3485-3492.
31. Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 2006; 296:1507-1517.
32. Deng G, Bell I, Crawley S, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1 but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004; 10:191-195.
33. Domingo E, Niessen RC, Oliveira C, et al. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene 2005; 24:3995-3998.
34. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nature Genetics 2006; 38:787-793.
35. Dove-Edwin I, Sasieni P, Adams J, et al. Prevention of colorectal cancer by colonsoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. Brit Med J 2005; 331:1047.
36. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349:247-257.
37. Jover R, Zapater P, Castells A, et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 2006; 55:848-855.
38. Offit K, Kohut K, Clagett B, et al. Cancer genetic testing and assisted reproduction. J Clin Oncol 2006; 24:4775-4782.